ClinicalTrials.gg
CompletedNCT01611883Updated May 24, 2024Results posted

A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)

A Phase 4 interventional study of Ezetimibe and Placebo in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
46th of 97
152 · median 148
Started
2012
with 1 other
Phase 4
31 of 98
1 open now
Registered
69th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 46th largest by enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2012, is one of 31 in phase 4, and was the 69th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will examine the effect of ezetimibe on glucose metabolism in participants with Type 2 diabetes and hypercholesterolemia.The primary hypothesis is that change in glycated hemoglobin (HbA1c) from baseline in the ezetimibe treatment group will be non-inferior to the placebo control group.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have hypercholesterolemia (high cholesterol) and have been diagnosed with type 2 diabetes that is being treated with oral anti-diabetic drugs or insulin or both.
  • No change in the medication (drugs, dose and administration) for the treatment of diabetes within previous 12 weeks with exception of small changes in insulin dosing
  • No change in diet and exercise therapy within previous 4 weeks

Exclusion criteria

Exclusion Criteria:

  • Coexisting disease (hemoglobinopathy, hemolytic anemia, etc.) that may affect measurement
  • Homozygous or heterozygous familial hypercholesterolemia
  • Previously received ezetimibe
  • Hypercholesterolemia associated with: hypothyroidism, obstructive gall bladder or biliary disease, chronic renal failure or pancreatitis
  • Hyperlipidemia caused by medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Ezetimibe

    10 mg oral dose once daily for 24 weeks

    Drug: Ezetimibe

  • Placebo comparator
    Placebo

    Placebo to match ezetimibe orally once daily for 24 weeks

    Drug: Placebo

Interventions

  • 10 mg oral dose once daily for 24 weeks

    Also known as: MK-0653, SCH 058235

  • DrugPlacebo

    Placebo to match ezetimibe orally once daily for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Hemoglobin (HbA1c) From Baseline

    HbA1c is blood marker used to report average blood glucose levels over a prolonged period of time and is reported as a percentage (%). HbA1C was measured at baseline and after 24 weeks of study drug administration.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change in Glycoalbumin From Baseline

    Glycoalbumin is a blood marker used to assess blood glucose control over time and is reported as a percentage (%). Serum glycoalbumin levels were assessed at baseline and after 24 weeks of study drug administration.

    Time frame: Baseline and Week 24

  2. Change in Fasting Plasma Glucose (FPG) From Baseline

    Plasma glucose levels were assessed after an overnight fast at baseline and after 24 weeks of study drug administration.

    Time frame: Baseline and Week 24

  3. Percentage of Participants With Adverse Event (AE) "Exacerbation of Diabetes"

    The Investigator took into account a participant's index of blood glucose control, diabetes medications, and compliance to diet and exercise therapy to assess overall control of the participant's diabetes and to determine if the participant's diabetes worsened. Participants who experienced the AE "Exacerbation of Diabetes " (verbatim term) were recorded.

    Time frame: up to 24 weeks

  4. Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes

    The percentage of participants who had changes to their medications used to treat their diabetes, other than small changes in insulin dosing (± 5 Units), were reported and summarized.

    Time frame: Up to 24 weeks

  5. Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline

    LDL-C levels measured at baseline and after 24 weeks of treatment

    Time frame: Baseline and Week 24

  6. Percent Change in Total Cholesterol (TC) From Baseline

    TC levels measured at Baseline and after 24 weeks of treatment.

    Time frame: Baseline and Week 24

  7. Percent Change in Triglycerides From Baseline

    Triglycerides levels measured at baseline and after 24 weeks of treatment.

    Time frame: Baseline and Week 24

  8. Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline

    HDL-C levels measured at baseline and after 24 weeks of treatment.

    Time frame: Baseline and Week 24

  9. Percent Change in Non-HDL-cholesterol From Baseline

    Non-HDL-C levels measured at baseline and after 24 weeks of treatment.

    Time frame: Baseline and Week 24

07

Results

Posted Dec 17, 2014

Participant flow

Participant flow — Overall Study
MilestoneEzetimibePlacebo
Started7577
Completed7476
Not completed11
Withdrew: Adverse event11

Outcome measures

PrimaryChange in Glycated Hemoglobin (HbA1c) From Baseline

HbA1c is blood marker used to report average blood glucose levels over a prolonged period of time and is reported as a percentage (%). HbA1C was measured at baseline and after 24 weeks of study drug administration.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent
Change in Glycated Hemoglobin (HbA1c) From Baseline
PercentEzetimibePlacebo
Change in Glycated Hemoglobin (HbA1c) From Baseline0.22 (0.11 to 0.34)0.14 (0.03 to 0.25)
Statistical analysis
  • Ezetimibe vs Placebo · Longitudinal analysis of covariance · Difference in least-squares means: 0.08 · 95% CI -0.07 to 0.23ezetimibe minus placebo
SecondaryChange in Glycoalbumin From Baseline

Glycoalbumin is a blood marker used to assess blood glucose control over time and is reported as a percentage (%). Serum glycoalbumin levels were assessed at baseline and after 24 weeks of study drug administration.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent
Change in Glycoalbumin From Baseline
PercentEzetimibePlacebo
Change in Glycoalbumin From Baseline-0.02 (-0.37 to 0.34)-0.02 (-0.37 to 0.33)
Statistical analysis
  • Ezetimibe vs Placebo · Longitudinal analysis of covariance · Difference in least-squares means: 0.00 · 95% CI -0.47 to 0.47ezetimibe minus placebo
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline

Plasma glucose levels were assessed after an overnight fast at baseline and after 24 weeks of study drug administration.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change in Fasting Plasma Glucose (FPG) From Baseline
mg/dLEzetimibePlacebo
Change in Fasting Plasma Glucose (FPG) From Baseline6.6 (1.1 to 12.1)11.4 (6.1 to 16.7)
Statistical analysis
  • Ezetimibe vs Placebo · Longitudinal Analysis of Covariance · Difference in least-squares means: -4.8 · 95% CI -12.1 to 2.5ezetimibe minus placebo
SecondaryPercentage of Participants With Adverse Event (AE) "Exacerbation of Diabetes"

The Investigator took into account a participant's index of blood glucose control, diabetes medications, and compliance to diet and exercise therapy to assess overall control of the participant's diabetes and to determine if the participant's diabetes worsened. Participants who experienced the AE "Exacerbation of Diabetes " (verbatim term) were recorded.

Time frame:
up to 24 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Event (AE) "Exacerbation of Diabetes"
Percentage of ParticipantsEzetimibePlacebo
Percentage of Participants With Adverse Event (AE) "Exacerbation of Diabetes"9.37.8
Statistical analysis
  • Ezetimibe vs Placebo · Fisher Exact · p = 0.779
SecondaryPercentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes

The percentage of participants who had changes to their medications used to treat their diabetes, other than small changes in insulin dosing (± 5 Units), were reported and summarized.

Time frame:
Up to 24 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes
Percentage of ParticipantsEzetimibePlacebo
Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes9.35.2
Statistical analysis
  • Ezetimibe vs Placebo · Fisher Exact · p = 0.365
SecondaryPercent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline

LDL-C levels measured at baseline and after 24 weeks of treatment

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline
Percent ChangeEzetimibePlacebo
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline-22.79 (-25.81 to -19.78)-1.75 (-4.73 to 1.24)
Statistical analysis
  • Ezetimibe vs Placebo · Longitudinal analysis of covariance · p = <0.001 · Difference in least-squares means: -21.05 · 95% CI -25.06 to -17.03ezetimibe minus placebo
SecondaryPercent Change in Total Cholesterol (TC) From Baseline

TC levels measured at Baseline and after 24 weeks of treatment.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Percent Change in Total Cholesterol (TC) From Baseline
Percent ChangeEzetimibePlacebo
Percent Change in Total Cholesterol (TC) From Baseline-15.01 (-17.34 to -12.68)-1.47 (-3.77 to 0.84)
Statistical analysis
  • Ezetimibe vs Placebo · Longitudinal analysis of covariance · p = <0.001 · Difference in least-squares means: -13.54 · 95% CI -16.66 to -10.42ezetimibe minus placebo
SecondaryPercent Change in Triglycerides From Baseline

Triglycerides levels measured at baseline and after 24 weeks of treatment.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Percent Change in Triglycerides From Baseline
Percent ChangeEzetimibePlacebo
Percent Change in Triglycerides From Baseline-7.52 (-14.97 to -0.08)3.83 (-3.57 to 11.23)
Statistical analysis
  • Ezetimibe vs Placebo · Longitudinal Analysis of Covariance · p = 0.025 · Difference in least-squares means: -11.36 · 95% CI -21.27 to -1.44ezetimibe minus placebo
SecondaryPercent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline

HDL-C levels measured at baseline and after 24 weeks of treatment.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline
Percent ChangeEzetimibePlacebo
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline3.86 (0.77 to 6.96)1.41 (-1.64 to 4.47)
Statistical analysis
  • Ezetimibe vs Placebo · Longitudinal Analysis of Covariance · p = 0.246 · Difference in least-squares means: 2.45 · 95% CI -1.71 to 6.61ezetimibe minus placebo
SecondaryPercent Change in Non-HDL-cholesterol From Baseline

Non-HDL-C levels measured at baseline and after 24 weeks of treatment.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Percent Change in Non-HDL-cholesterol From Baseline
Percent ChangeEzetimibePlacebo
Percent Change in Non-HDL-cholesterol From Baseline-21.32 (-24.05 to -18.59)-2.25 (-4.95 to 0.45)
Statistical analysis
  • Ezetimibe vs Placebo · Longitudinal Analysis of Covariance · p = <0.001 · Difference in least-squares means: -19.07 · 95% CI -22.71 to -15.43ezetimibe minus placebo

Adverse events

Collected over up to 24 weeks for non-serious adverse events (AEs); up to 28 weeks for serious AEs. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe—2/75 (2.7%)17/75 (22.7%)
Placebo—5/77 (6.5%)25/77 (32.5%)
Most frequent serious events
Most frequent serious events
EventEzetimibePlacebo
CATARACTEye disorders1/750/77
ABDOMINAL PAIN UPPERGastrointestinal disorders1/750/77
ANGINA PECTORISCardiac disorders0/751/77
ANGINA UNSTABLECardiac disorders0/751/77
ACCIDENTAL OVERDOSEInjury, poisoning and procedural complications0/751/77
ANKLE FRACTUREInjury, poisoning and procedural complications0/751/77
SPINAL OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/751/77
Most frequent other events
Most frequent other events
EventEzetimibePlacebo
NASOPHARYNGITISInfections and infestations11/7513/77
TYPE 2 DIABETES MELLITUSMetabolism and nutrition disorders7/756/77
HYPOGLYCAEMIAMetabolism and nutrition disorders2/757/77
PHARYNGITISInfections and infestations0/754/77

Baseline characteristics

Age, Continuous
Age, Continuous(years)EzetimibePlaceboTotal
Mean59.3 ± 10.860.0 ± 9.759.6 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)EzetimibePlaceboTotal
Female292958
Male464894
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Saito I, Azuma K, Kakikawa T, Oshima N, Hanson ME, Tershakovec AM. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 2015 May 1;14:40. doi: 10.1186/s12944-015-0036-z. PubMed 25929253 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Jan 2014, 18 months.

Results were first posted in Dec 2014, 11 months after primary completion.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2012
First posted
Jun 5, 2012
StartActual
Jul 2, 2012
Primary completionActual
Jan 16, 2014
CompletionActual
Jan 16, 2014
Results first posted
Dec 17, 2014
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01611883
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jun 5, 2012
Start date
Jul 2, 2012
Primary completion
Jan 16, 2014
Completion
Jan 16, 2014
Results posted
Dec 17, 2014
Last update
May 24, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion